BMC Veterinary Research (Feb 2023)

Metallothionein expression in feline injection site fibrosarcomas

  • Mateusz Mikiewicz,
  • Katarzyna Paździor-Czapula,
  • Joanna Fiedorowicz,
  • Michał Gesek,
  • Iwona Otrocka-Domagała

DOI
https://doi.org/10.1186/s12917-023-03604-5
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Feline injection site fibrosarcoma is an aggressive and infiltrative tumour arising in the background of chronic inflammation. The aim of this study was to evaluate the expression of metallothionein (I-II) in feline injection site fibrosarcomas and to assess its possible relationships with Ki67 index, inflammation score and tumour grade. The study included 40 feline fibrosarcomas, located in the common injection sites (i.e., interscapular area, thigh, flank), constituting archival diagnostic specimens collected between 2019–2020. Tumours were graded histologically according to the newly proposed soft-tissue sarcoma grading system in cats. Immunohistochemistry was performed to evaluate the expression of Ki67 and metallothionein in tumour cells. Results The cytoplasmic and sometimes nuclear expression of metallothionein was observed in all tumours grade I, 66.67% of tumours grade II and 55% of tumours grade III. The expression of metallothionein was negatively correlated with tumour grade and inflammation score, while the Ki67 index was positively correlated with tumour grade, inflammation score and necrosis score. Conclusion The downregulation of MT expression in feline injection site fibrosarcomas seems to be connected with an increase in the inflammatory infiltration, hence tumour progression. This is the first study describing metallothionein expression in feline injection site fibrosarcomas.

Keywords